Drug Trial Radar · NCT01087671
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops
Last checked: Nov 20, 2026Latest source record: May 31, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
185
Actual
Start
Apr 2010
Primary completion
Oct 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- Santen OyIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.
Conditions
- Ocular Hypertension
- Open-Angle Glaucoma
Interventions
tafluprostDrug
prostaglandin analogue
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of changes in ocular symptoms and signsTime frame: From Screening (Visit 1) to12 weeks.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.